BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives $390.92 Consensus PT from Analysts

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have received an average recommendation of “Moderate Buy” from the fifteen analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $390.9231.

ONC has been the subject of several recent analyst reports. Barclays reduced their price objective on shares of BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating for the company in a research report on Tuesday, July 14th. Truist Financial increased their target price on shares of BeOne Medicines from $413.00 to $416.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Zacks Research lowered shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Friday. Finally, Guggenheim upped their price objective on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th.

Insider Transactions at BeOne Medicines

In related news, COO Xiaobin Wu sold 1,292 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $276.26, for a total value of $356,927.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Lai Wang sold 1,068 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $276.74, for a total value of $295,558.32. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 233,647 shares of company stock worth $70,335,553 over the last three months. 6.19% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ONC. Generali Investments Management Co LLC purchased a new position in shares of BeOne Medicines during the second quarter worth approximately $2,280,000. Charles Schwab Trust Co acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at $855,000. Steadtrust LLC raised its position in BeOne Medicines by 3.7% in the 2nd quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock valued at $399,000 after purchasing an additional 50 shares during the last quarter. Empowered Funds LLC purchased a new stake in BeOne Medicines in the 1st quarter valued at $201,000. Finally, Bank of America Corp DE raised its position in BeOne Medicines by 7.0% in the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after purchasing an additional 26,441 shares during the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $310.58 on Friday. The stock’s 50-day simple moving average is $290.21 and its 200-day simple moving average is $308.99. The firm has a market capitalization of $34.08 billion, a PE ratio of 69.48 and a beta of 0.49. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $385.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, equities research analysts forecast that BeOne Medicines will post 5.86 EPS for the current fiscal year.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.